istock-629794242xesai-1

Xesai / iStockphoto.com

7 June 2018Big Pharma

GSK completes buyout of Novartis from joint venture

GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More on this story

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More on this story

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility